Today's Brokerage Rating: Neurocrine Biosciences, Inc

12 Analysts reported that the Price Target for Neurocrine Biosciences Inc. might touch $96 high while the Average Price Target and Low price Target is $67 and $55 respectively. They noted that the move was a valuation call.

While taking a glance at financials, we can look at a number of key indicators about Neurocrine Biosciences, Inc.'s (NBIX).

More analysts at Reuters have a buy or better ratings (12) on the Neurocrine Biosciences, Inc. stock than those who have a hold (0) rating while the 12-month target price suggested by the average analysts is $66.92. The company has an average rating of Buy and an average price target of $65.69. Neurocrine Biosciences now has a consensus rating of "Buy" and a consensus target price of $65.69. The company has a market cap of $3,608 million and there are 86,871,313 shares in outstanding. The stock's current distance from 20-Day Simple Moving Average (SMA20) is 0.55% where SMA50 and SMA200 are 0.84% and -9.24% respectively. The stock appeared $55.15 above its 52-week highs and is down -2.54% for the last five trades. The difference between the expected and actual EPS was $0.14/share, which represents an Earnings surprise of 24.6%. During the same period in the prior year, the company earned ($0.34) EPS.

Neurocrine shares have climbed slightly more than 7 percent since the beginning of the year.

Nonetheless, and in the immediate aftermath of reporting, investor reaction in Neurocrine Biosciences, Inc. If you are accessing this report on another website, it was illegally stolen and republished in violation of United States & worldwide copyright & trademark legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2017/02/15/neurocrine-biosciences-inc-nbix-given-outperform-rating-at-robert-w-baird.html. The firm owned 802,979 shares of the company's stock after selling 209,227 shares during the period.

Several company insiders have filed Insider transactions, on Feb 8, 2017, Dimitri E. Grigoriadis (Chief Research Officer) sold 727 shares at $43.13 per share price. The shares were sold at an average price of $43.35, for a total value of $75,862.50. Also, Director William H. Rastetter sold 10,750 shares of the company's stock in a transaction that occurred on Wednesday, February 1st. The disclosure for this sale can be found here.

"7" Analysts are expecting that the company to declare next quarterly earnings of $-0.60 per share for period Quarter Ending_Jun-17. Finally, Oppenheimer Holdings, Inc. began coverage on shares of Neurocrine Biosciences in a research report on Tuesday, November 22nd. First Mercantile Trust Co. now owns 3,897 shares of the company's stock valued at $197,000 after buying an additional 1,897 shares during the last quarter.

August 03, 2016: Neurocrine Biosciences, Inc. Two Sigma Securities LLC bought a new position in shares of Neurocrine Biosciences during the third quarter worth about $212,000. Finally, SECOR Capital Advisors LP purchased a new position in shares of Neurocrine Biosciences during the third quarter valued at about $260,000.

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders.

  • Arturo Norris